96 related articles for article (PubMed ID: 21372151)
1. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia.
Nuche-Berenguer B; Lozano D; Gutiérrez-Rojas I; Moreno P; Mariñoso ML; Esbrit P; Villanueva-Peñacarrillo ML
J Endocrinol; 2011 May; 209(2):203-10. PubMed ID: 21372151
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.
Nuche-Berenguer B; Moreno P; Portal-Nuñez S; Dapía S; Esbrit P; Villanueva-Peñacarrillo ML
Regul Pept; 2010 Jan; 159(1-3):61-6. PubMed ID: 19586609
[TBL] [Abstract][Full Text] [Related]
3. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.
Ma X; Meng J; Jia M; Bi L; Zhou Y; Wang Y; Hu J; He G; Luo X
J Bone Miner Res; 2013 Jul; 28(7):1641-52. PubMed ID: 23427056
[TBL] [Abstract][Full Text] [Related]
4. Amylin and bone metabolism in streptozotocin-induced diabetic rats.
Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP
J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342
[TBL] [Abstract][Full Text] [Related]
5. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
[TBL] [Abstract][Full Text] [Related]
6. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
7. Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals.
Malendowicz LK; Nowak KW
Int J Mol Med; 2002 Sep; 10(3):327-31. PubMed ID: 12165809
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.
Sonne DP; Engstrøm T; Treiman M
Regul Pept; 2008 Feb; 146(1-3):243-9. PubMed ID: 17976835
[TBL] [Abstract][Full Text] [Related]
10. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Wang Y; Perfetti R; Greig NH; Holloway HW; DeOre KA; Montrose-Rafizadeh C; Elahi D; Egan JM
J Clin Invest; 1997 Jun; 99(12):2883-9. PubMed ID: 9185511
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus.
Brunetti L; Orlando G; Recinella L; Leone S; Ferrante C; Chiavaroli A; Lazzarin F; Vacca M
Peptides; 2008 Aug; 29(8):1377-81. PubMed ID: 18502539
[TBL] [Abstract][Full Text] [Related]
15. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio.
Rauner M; Stupphann D; Haas M; Fert I; Glatigny S; Sipos W; Breban M; Pietschmann P
J Rheumatol; 2009 Jan; 36(1):120-6. PubMed ID: 19040304
[TBL] [Abstract][Full Text] [Related]
16. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1.
Cani PD; Neyrinck AM; Maton N; Delzenne NM
Obes Res; 2005 Jun; 13(6):1000-7. PubMed ID: 15976142
[TBL] [Abstract][Full Text] [Related]
17. The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy.
Narusawa K; Nakamura T; Suzuki K; Matsuoka Y; Lee LJ; Tanaka H; Seino Y
J Bone Miner Res; 1995 Dec; 10(12):1853-64. PubMed ID: 8619365
[TBL] [Abstract][Full Text] [Related]
18. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels.
Li L; Yang G; Li Q; Tan X; Liu H; Tang Y; Boden G
Diabetes Obes Metab; 2008 Sep; 10(10):921-30. PubMed ID: 18093209
[TBL] [Abstract][Full Text] [Related]
19. Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat.
Sebokova E; Bénardeau A; Sprecher U; Sewing S; Tobalina L; Migliorini C
Diabetes Obes Metab; 2010 Aug; 12(8):674-82. PubMed ID: 20590744
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
